Authors

Kathleen Moore, MD, The University of Oklahoma Health

Latest:

Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Kathleen N. Moore, MD, Stephenson Cancer Center

Latest:

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

Kathleen N. Moore, MD, University of Oklahoma

Latest:

Advanced Endometrial Cancer

Kathleen Toomey, MD

Latest:

Dr. Toomey on the Importance of De-Escalation Clinical Trials in HER2+ Breast Cancer

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

Kathryn A. Gold, MD

Latest:

Dr Gold on the Benefit of Targeted Therapies in Mutated Lung Cancers

Kathryn A. Gold, MD, discusses the benefit of targeted therapies in patients with mutated lung cancers.

Kathryn Bollin, MD

Latest:

A Comprehensive Look at Palliative Care: What Every Fellow Should Understand

Kathryn Bollin, MD, writes about the importance of enlisting palliative care at the right time, as a critical step that must be taken by any team striving to provide expert cancer care.

Kathryn Canavan

Latest:

Survivorship Care Plans: Should Every Patient Have One?

The number of cancer survivors in the United States has quadrupled since 1971, making it imperative for healthcare professionals to identify and address the needs of this burgeoning population.

Kathryn Ciccolini, RN, BSN, OCN

Kathryn Ciccolini, RN, BSN, OCN, DNC

Latest:

Kathryn Ciccolini Discusses the CREAM Principles to Manage Dermatologic AEs

Kathryn Ciccolini, RN, BSN, OCN, DNC, Memorial Sloan Kettering Cancer Center, discusses the concept she developed to manage dermatologic adverse events for patients with cancer.

Kathryn E. Beckermann, MD, PhD

Latest:

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Kathryn E. Hudson, MD

Latest:

Dr. Hudson on the Utility of Liquid Biopsy in Lung Cancer

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Kathryn Kolibaba, MD

Latest:

Dr. Kolibaba on Efficacy of Entospletinib in Mantle Cell Lymphoma

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).

Kathryn Mileham, MD

Latest:

Dr. Mileham Discusses Biomarkers in Lung Cancer

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

Kathryn Ruddy, MD

Latest:

Dr. Ruddy on the Use of GnRH Agonists in Breast Cancer

Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.

Kathy Boltz, PhD

Latest:

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

Kathy J. Schilling, MD

Latest:

Dr. Schilling on Dense Breast Tissue Detection Methods

Kathy J. Schilling, MD, a radiologist at Boca Raton Regional Hospital, discusses the importance of additional screening for women with dense breasts.

Kathy S. Albain, MD

Latest:

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Kathy W. Oubre, MS

Latest:

It Takes a Village, Not a Navigator

Pontchartrain Cancer Center was faced with the same dilemma most community-based independents have dealt with: reinvent the practice or join a hospital.

Katie Eder

Latest:

Cancer-Related Pain Fraught With Therapeutic and Ethical Complexities

As long-term cancer survival rates continue to surge, an increasing percentage of patients with cancer-related pain are progressing to the chronic pain arena, which necessitates more contemporary treatment approaches to cancer pain management.